Results 1 to 10 of about 151,922 (279)

Pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy for esophageal cancer

Radiation Oncology, 2020
Background The literature regarding pericardial effusion after definitive concurrent chemotherapy and intensity modulated radiotherapy (IMRT) for esophageal cancer was lacking.
Tzu-Hui Pao, Wei-Lun Chang, Nai-Jung Chiang, Chia-Ying Lin, Wu-Wei Lai, Yau-Lin Tseng, Forn-Chia Lin   +6 more
doaj   +2 more sources

Pericardial effusion in oncological patients: current knowledge and principles of management

Cardio-Oncology
Background This article provides an up-to-date overview of pericardial effusion in oncological practice and a guidance on its management. Furthermore, it addresses the question of when malignancy should be suspected in case of newly diagnosed pericardial
S. Mori, M. Bertamino, L. Guerisoli, S. Stratoti, C. Canale, P Spallarossa, I. Porto, P. Ameri   +7 more
doaj   +2 more sources

Pericardial effusion under nivolumab: case-reports and review of the literature

Journal for ImmunoTherapy of Cancer, 2019
Background Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related adverse events are frequent under
Saade Anastasia, Mansuet-Lupo Audrey, Arrondeau Jennifer, Thibault Constance, Mirabel Mariana, Goldwasser François, Oudard Stéphane, Weiss Laurence   +7 more
doaj   +2 more sources

Chronic massive pericardial effusion: a case report and literature review

Journal of International Medical Research, 2020
Chronic massive pericardial effusion without cardiac tamponade is relatively rare. Nearly half of all patients with chronic large pericardial effusion are asymptomatic.
Ying-shuo Huang, Jian-xiong Zhang, Ying Sun   +2 more
doaj   +2 more sources

Pericardial effusion [PDF]

Jornal Brasileiro de Pneumologia, 2021
Edson Marchiori, Bruno Hochhegger, Gláucia Zanetti   +2 more
openaire   +4 more sources

Echocardiographic Evaluation of Pericardial Effusion and Cardiac Tamponade

Frontiers in Pediatrics, 2017
Pericardial effusion (PEff) is defined by an increase in the physiological amount of fluid within the pericardial space. It can appear following different medical conditions, mainly related to inflammation and cardiac surgery.
Sergi Cesar, Joan Sanchez-de-toledo
exaly   +2 more sources

Pericardial Effusion With Tamponade in Lung Cancer Patients During Treatment With Nivolumab: A Report of Two Cases

Frontiers in Oncology, 2019
Background: Nivolumab is an immune checkpoint inhibitor (ICI) that has shown efficacy for treating non-small cell lung cancer and has become a standard therapy for previously treated non-small cell lung cancer.
Masahiro Yamasaki, Wakako Daido, Naomi Saito, Kunihiko Funaishi, Takenori Okada, Kazuma Kawamoto, Yu Matsumoto, Naoko Matsumoto, Masaya Taniwaki, Nobuyuki Ohashi, Nobuyuki Ohashi, Noboru Hattori   +11 more
doaj   +2 more sources

Massive Idiopathic Chronic Pericardial Effusion: A Case Report [PDF]

Journal of Cardio-Thoracic Medicine, 2023
An idiopathic chronic pericardial effusion which has occurred due to pericardial fluid collection can continue for over a three-month duration without obvious cause. Massive chronic pericardial effusion without cardiac tamponade is quite unusual.
Mahdi Kahrom, Masoomeh Tabari
doaj   +1 more source

Pericardial Effusion on MRI in Autosomal Dominant Polycystic Kidney Disease

Journal of Clinical Medicine, 2022
Autosomal dominant polycystic kidney disease (ADPKD) has been associated with cardiac abnormalities including mitral valve prolapse and aneurysmal dilatation of the aortic root.
Jin Liu, K. Fujikura, Hreedi Dev, Sadjad Riyahi, J. Blumenfeld, Jiwon Kim, H. Rennert, M. Prince   +7 more
semanticscholar   +1 more source

Tegafur‐uracil‐induced pericardial effusion during adjuvant chemotherapy for resected lung adenocarcinoma: A case report

Thoracic Cancer, 2021
In Japan, oral administration of tegafur‐uracil is recommended as postoperative adjuvant chemotherapy for patients diagnosed with primary lung adenocarcinomas of >2 cm size and staged as IA, IB, and IIA.
Nobutaka Kawamoto, Riki Okita, Masataro Hayashi, Masanori Okada, Hidetoshi Inokawa   +4 more
doaj   +1 more source